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T R A N S F U S I O N  C O M P L I C A T I O N S
 
West Nile virus blood transfusion-related infection despite nucleic 
acid testing
 
Alexandre Macedo de Oliveira, Brady D. Beecham, Susan P. Montgomery, Robert S. Lanciotti, 
Jeffrey M. Linnen, Cristina Giachetti, Larry A. Pietrelli, Susan L. Stramer, and Thomas J. Safranek
 
BACKGROUND:
 
 A case of West Nile virus (WNV) 
encephalitis associated with transfusion of blood that did 
not react when tested for WNV by minipool (MP) nucleic 
acid testing (NAT) is described. A Nebraska man 
developed clinical encephalitis 13 days after surgery and 
transfusion of 26 blood components. Antibody testing 
confirmed WNV infection. An investigation was initiated to 
determine the source of this infection.
 
STUDY DESIGN AND METHODS:
 
 The patient’s family 
members were interviewed to identify risk factors for WNV 
infection. Residual samples were retested for WNV RNA 
using transcription-mediated amplification (TMA) assay 
and two polymerase chain reaction (PCR) assays. Blood 
donors’ follow-up serum samples were collected. All 
samples were tested for WNV-specific immunoglobulin M 
antibodies.
 
RESULTS:
 
 The patient’s family denied recent mosquito 
exposure. The 20 blood components collected after July 
2003 did not react when tested for WNV in a six-member 
MP-NAT at the time of donation. Retrospective individual 
testing identified one sample as WNV-reactive by the TMA 
assay and one of the PCR assays. Seroconversion was 
demonstrated in the donor associated with this sample.
 
CONCLUSION:
 
 WNV RNA detection by individual 
donation NAT demonstrates viremic blood escaping MP-
NAT and supports transfusion-related WNV transmission. 
MP-NAT may not detect all WNV-infected blood donors, 
allowing WNV transmission to continue at low levels. WNV 
NAT assays might vary in sensitivity and pooling 
donations could further impact test performance.
Understanding MP NAT limitations can improve strategies 
to maintain safety of the blood supply in the United States. 
 
est Nile virus (WNV), a mosquito-borne
flavivirus, was initially seen in the US in
1999 and first reported among Nebraska
residents in 2002.
 
1,2
 
 Humans serve as inci-
dental hosts, and most infections are asymptomatic;
approximately 30 percent of infections result in a non-
neuroinvasive disease known as West Nile fever, and less
than 1 percent of infected individuals develop severe dis-
eases such as meningitis and/or encephalitis.
 
3-5
 
 In the US,
a total of 9862 human cases of WNV disease were reported
in 45 states and the District of Columbia in 2003. Nebraska
reported more than 1900 human WNV cases in 2003, rank-
ing second only to Colorado.
 
6
 
 Blood transfusion-related
transmission of WNV infection during the 2002 US epi-
demic prompted rapid development of two investiga-
tional nucleic acid testing (NAT) assays to screen donated
blood for WNV viremia: the TaqScreen WNV test (Roche
W
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Molecular Systems Inc., Pleasanton, CA) and the Procleix
WNV assay (Gen-Probe Inc., San Diego, CA).
 
7,8
 
 (Use of
trade names is for identification purposes only and does
not constitute endorsement by the US Public Health Ser-
vice or the Centers for Disease Control and Prevention
[CDC].) The tests were implemented between June and
August 2003.
 
9,10
 
 Because of automation constraints, the
tests are performed with minipools (MPs) of either six
(TaqScreen assay) or 16 (Procleix assay) donations. A lim-
ited number of blood centers have the capacity to rou-
tinely screen by individual donation testing (IDT); in
addition, some programs converted to IDT for limited
periods during the 2003 epidemic. Donated blood from
reactive pools is individually retested to identify the WNV-
reactive donation. Donors associated with WNV-reactive
individual tests are deferred from donation for at least
4 weeks. The WNV-reactive donation and any of that
donor’s unexpired blood components obtained in the
28 days before the reactive tests are discarded. In this
report, we describe the investigation of a patient who
developed WNV encephalitis after receiving blood that
had did not react with NAT for WNV in a six-member MP.
 
CASE REPORT
 
On August 4, 2003, an 80-year-old Nebraska man under-
went open-heart surgery. During surgery, the patient
received 26 blood components because of massive bleed-
ing: 8 units of red blood cells, 6 units of fresh frozen
plasma (FFP), 2 units of single-donor platelets (PLTs), and
10 units of random-donor PLTs. The patient recovered and
was discharged to home 10 days later.
On August 19, 2003, 15 days after trans-
fusion, the patient was rehospitalized
after experiencing mental confusion
and fever for 2 days. The patient’s con-
dition worsened, and he was placed on
ventilatory support for 3 weeks. His
condition gradually improved, and he
was subsequently transferred to a reha-
bilitation facility.
WNV encephalitis was suspected,
and serum and cerebrospinal fluid were
collected during the second hospitaliza-
tion. These tested positive for the pres-
ence of WNV-specific immunoglobulin
M (IgM) antibodies at the Nebraska
Public Health Laboratory (Table 1).
On September 10, 2003, 37 days
after transfusion, a convalescent serum
sample was collected from the patient.
This sample tested positive for the pres-
ence of WNV by WNV-specific IgM
enzyme-linked immunosorbent assay
(ELISA) and WNV plaque reduction
neutralization test (PRNT) and negative for the presence
of St Louis encephalitis (SLE) by PRNT at the CDC
(Table 1).
Upon receipt of the first positive WNV IgM test, the
hospital infection-control practitioners notified the Office
of Epidemiology at the Nebraska Health and Human Ser-
vices System and an investigation was launched to deter-
mine the source of this infection.
 
MATERIALS AND METHODS
 
Family members of the infected patient were interviewed
in August 2003 to evaluate the potential for mosquito
exposure after surgery. In addition, all transfused blood
components were identified and traced to their donors.
Residual samples from the donation testing tubes and
unused  co-components  were  located  and  stored  frozen
(
 
-
 
20
 
∞
 
C). Implicated donors were interviewed about symp-
toms consistent with WNV infection, and a follow-up
blood sample was collected in September 2003.
Quarantined residual samples were tested individu-
ally for the presence of WNV RNA with three different lab-
oratory tests: the two investigational assays used for WNV
blood donor screening and an in-house assay. The tests
were a transcription-mediated amplification assay (Pro-
cleix WNV assay, Gen-Probe Inc.) and two different
dynamic quantitative polymerase chain reaction (PCR)
assays: TaqScreen WNV test (Roche Molecular Systems
Inc.) and an in-house PCR (CDC, Fort Collins, CO).
 
11-13
 
Reactive specimens were further tested with the commer-
cial assays: 10 replicates with undiluted samples and 10
 
TABLE 1. Laboratory tests performed on the index patient at time 
of readmission and convalescence, Nebraska, 2003
 
Laboratory study Collection date Result Normal values
Hemoglobin (g/100 mL) 8/20/2003 11 13.5-17.0
WBC count (
 
¥
 
10
 
3
 
 cells/mm
 
3
 
) 8/20/2003 9  4-10
Differential (%)
Neutrophils 57  40-80
Lymphocytes 39  20-45
Monocytes 3  0-10
Eosinophils 1  0-7
Basophils 0  0-2
Serum
Glucose (mg/dL) 8/20/2003 103  65-120
Protein (g/dL) 8/20/2003 6.1 6.0-8.3
CSF*
Glucose (mg/dL) 8/20/2003 58
 
<
 
105
Protein (mg/dL) 8/20/2003 98.4
 
<
 
42
WBC count (cells/mm
 
3
 
) 8/20/2003 155
 
<
 
3
Mononuclear (%) 39
Segmented neutrophils (%) 61
Arbovirus studies
WNV IgM (serum) 8/20/2003 Positive Negative
WNV IgM (CSF) 8/20/2003 Positive Negative
WNV IgM (serum) 9/10/2003 Positive Negative
WNV PRNT 9/10/2003 Positive Negative
SLE PRNT 9/10/2003 Negative Negative
* CSF 
 
=
 
 cerebrospinal fluid.
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with MP-dilution levels (1:6 for the TaqScreen assay and
1:16 for the Procleix assay). Viral load of reactive speci-
mens was determined by quantitative PCR (SuperQuant
for WNV, National Genetics Institute, Los Angeles, CA) and
through dilutional studies at CDC and Gen-Probe Inc.
Residual samples from donations and follow-up sam-
ples were tested with WNV IgM antibody-capture ELISA.
WNV infection was confirmed with PRNT for WNV and
SLE.
 
14
RESULTS
 
Exposure assessment
 
Family members denied recent mosquito exposure,
reporting that the patient was hospitalized or bedridden
at home during the 2 weeks before symptom onset. The
infected patient received 26 blood components from 26
different donors. These donations generated 41 additional
blood components: 18 were transfused to other patients,
17 were quarantined, and 6 were discarded before our
investigation began.
Six of the 26 donations took place in February 2003
and had no residual samples available at the time of inves-
tigation. The remaining 20 donations were made in July
and August 2003. Thirteen of these had approximately
200 mL of quarantined FFP available for testing; the other
7 had approximately 2 mL of serum remaining.
 
Results from donations
 
The CDC PCR, the investigational TaqScreen assay, and
the investigational Procleix assay were all carried out on
the 13 high-volume specimens by the developers of each
test. One specimen reacted by the Procleix assay, equivo-
cal by the CDC PCR, and did not react by the TaqScreen
assay. A subsequent CDC PCR assay with an increased
RNA extraction volume reacted. The viral load in this sam-
ple was estimated to be 560 copies per mL by the Super-
Quant assay and 40 and 30 copies per mL by CDC and
Gen-Probe Inc., respectively. Replicate results with the
Procleix assay showed reactivity in all 10 replicates with
undiluted samples and in 3 of 10 at 1:16 dilution. The
TaqScreen assay exhibited reactivity in 5 of 10 and 2 of 10
replicates at undiluted and 1:6-diluted samples, respec-
tively. This donation generated 1 unit of PLTs, which was
transfused to the index patient. The other 12 high-volume
samples did not react in all NAT assays.
The seven 2-mL specimens were aliquotted and sent
to CDC and the other test developers’ laboratories. They
all did not react by the CDC PCR and the Procleix assay.
Volume was insufficient for the TaqScreen assay.
WNV-specific IgM was negative for all 20 donations
that had residual samples available for testing. Test results
are shown in Table 2.
 
Donor follow-up
 
We obtained follow-up samples from 24 of the 26 donors
in mid-September 2003 and tested these for WNV-specific
IgM antibodies. The median interval between donation
and follow-up sample collection was 44 days (range, 38-
219 days). The donor associated with the NAT-positive
sample (Donor A) and two other donors tested positive for
IgM antibodies (Table 2). Confirmatory PRNT tests were
positive for the presence of WNV and negative for the pres-
ence of SLE on these three samples. These three donors
denied WNV symptoms during the 30 days before and
after donation.
 
Blood co-components from WNV-specific 
IgM-positive donors
 
The two additional blood components derived from
Donor A’s donation were not transfused. Units from the
other two IgM-positive donors were transfused to two
other patients. Both recipients were asymptomatic for
WNV. One tested negative for the presence of WNV IgM,
and the other declined testing.
 
TABLE 2. Test results obtained on donated blood and follow-up samples for the 26 donors, Nebraska, 2003
 
Donor
Original donation Follow-up sample
WNV IgM CDC PCR Procleix assay TaqScreen assay WNV IgM WNV PRNT SLE PRNT
A Negative Reactive* Reactive Did not react Positive Positive Negative
B Negative Did not react Did not react Did not react Positive Positive Negative
C Negative Did not react Did not react NA† Positive Positive Negative
D-M Negative Did not react Did not react Did not react Negative NA NA
N Negative Did not react Did not react Did not react NA NA NA
O-T Negative Did not react Did not react NA Negative NA NA
U-Y‡ NA NA NA NA Negative NA NA
Z‡ NA NA NA NA NA NA NA
* Test performed using high extraction volume.
† NA 
 
=
 
 not available.
‡ Donations from February 2003.
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DISCUSSION
 
This investigation describes a patient with WNV enceph-
alitis acquired through transfusion of WNV viremic blood
that went undetected by MP-NAT screening but reacted
for WNV by IDT. Our conclusion is supported by the detec-
tion of WNV RNA in one of the donations, followed by
seroconversion in the corresponding donor. The impli-
cated donor never developed symptomatic WNV infec-
tion. WNV RNA likely was present at levels below the
detection limit of the MP format.
Although this investigation suggests WNV blood
transfusion-related infection, it has three main limita-
tions. First, the infected patient could have contracted
WNV before surgery. Because no presurgical samples from
the infected patient were available for testing, excluding
existing infection was impossible. Second, it was not pos-
sible to rule out mosquito exposure as the mode of trans-
mission. The patient denied symptoms before surgery,
however, and his convalescent condition kept him hospi-
talized or indoors at home, making this other source of
infection unlikely. Finally, because two other seroconver-
sions were documented among these donors, we cannot
exclude the possibility of an alternate-source donor.
Recipients of co-components, however, from donated
blood from the seroconverters did not experience WNV
symptoms, nor was WNV RNA identified in residual sam-
ples from their donations. The high incidence of WNV
infection in Nebraska during summer 2003 makes it pos-
sible that these persons were infected after donating
blood.
Although the six donations from February 2003 were
not available for NAT, these donations occurred before
WNV was circulating in Nebraska. In addition, follow-up
samples from five of these donors were negative for the
presence of WNV-specific IgM antibodies, making them
an unlikely source of infection.
WNV blood transfusion-related infections were first
described during the 2002 epidemic.
 
7,8
 
 To minimize this
risk, the Food and Drug Administration (FDA) recom-
mended deferring donors reporting fever with headache
in the week before donation.
 
15
 
 In addition to the clinical
screening,  beginning  June  2003,  NAT  was  introduced  as
a blood-screening tool with protocols conducted under
FDA’s investigational new drug (IND) mechanisms.
 
9,10
 
Recognizing technology and resource constraints, the IND
protocols allowed for blood donation screening in MPs of
6 (TaqScreen assay) or 16 (Procleix assay) members. Pool-
ing donations may reduce assay sensitivity and increase
the possibility of missing donors with low-level viremia.
In this report, the six-member MP TaqScreen assay
performed on the donations did not react, and the blood
products were released for use in accordance with the IND
protocol. A patient developed WNV encephalitis 13 days
after transfusion with these products, a time frame com-
patible with WNV’s incubation period. Residual samples
from these donations were subsequently retested at three
laboratories. For one donation, samples tested with repli-
cate tests inconsistently reacted by the TaqScreen assay
but reacted by the Procleix assay. Viral quantitation of that
sample detected low levels of WNV RNA, although vari-
ability among quantitative results was observed. Dilu-
tional testing showed that the MP format compromised
test performance compared with IDT. The replicate test-
ing also indicated that differences in sensitivity might
exist between the investigational NAT assays. Further
evaluation is necessary to confirm these conclusions.
The timely development of WNV NAT and its imp-
lementation under the IND mechanism are the result of
an extraordinary effort by commercial laboratories, CDC,
FDA, and the blood-collection community to enhance the
safety of the blood supply in the US. In 2003, a total of 818
US blood donations were identified as “presumed
viremic,” which is defined as repeat reactivity on the same
or on a different NAT assay.
 
16
 
 The high number of viremic
donors with asymptomatic WNV infection highlights the
need for highly sensitive WNV-specific NAT to ensure
blood supply safety. In addition, strategies such as the
implementation of IDT in regions with high WNV infec-
tion rates should be considered.
NAT for human immunodeficiency virus-1 and hep-
atitis C virus has improved the identification of infected
donors and is universally performed by the US blood
industry, although it has been demonstrated to be cost-
ineffective by traditional expenditure versus benefit
estimates for medical interventions.
 
17-19
 
 NAT could be
cost-effective for WNV screening of the blood supply,
because seasonal incidence is high in certain geographic
areas, infection is asymptomatic in more than 80 percent
of cases, and long periods of viremia can occur.
 
20,21
 
WNV can be effectively transmitted through blood
transfusions. The burden of WNV blood transfusion-
related disease is probably underestimated owing to the
low rate of symptomatic disease among recipients and the
difficulty in establishing blood transfusion as the source
of WNV infection.
 
8
 
 The presence of infectious WNV in
donated blood necessitates the application of viral detec-
tion testing such as NAT. Additional studies are needed to
define the sensitivity of current NAT assays, their ability
to detect low-level viremic donations, and their cost-
effectiveness. This would allow optimization of testing
protocols.
Emerging infectious diseases pose risks to blood
safety.
 
22
 
 Health-care workers and public-health authorities
should maintain surveillance for the possibility of WNV
and other arboviral transmission through blood transfu-
sions. The development and implementation of WNV NAT
for blood screening has contributed to a decreased risk of
blood-borne transmission in the US. Nevertheless, low-
viremic donors may go undetected by MP-NAT.
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